I n his proposed budget for fiscal year 2018, President Donald Trump recommended eliminating the Fogarty International Center (FIC) at the National Institutes of Health (NIH). Although the NIH actually received increased funding in the fiscal year 2017 budget that was signed on May 5, the FIC -a leader of U.S. global health research efforts for the past 50 years -may be vulnerable in upcoming negotiations over the 2018 budget. NIH Director Francis Collins has signaled that while awaiting congressional guidance, he is evaluating whether he can justify continuing the FIC if the NIH faces budget cuts down the line. 1 In our view as current or past recipients of FIC support, the center represents a valuable and effective scientific and diplomatic investment, and the small reduction in the federal budget that would result from its elimination would be far outweighed by what would be lost.
The FIC mission is threefold: to advance NIH goals by supporting global health research conducted by U.S. and international investigators, to build partnerships between research institutions in the United States and abroad, and to train the next generation of scientists to address global health needs. The center's efforts have produced medical innovations that transcend borders. Its closure would not only be detrimental for global health but would also affect the health of Americans and impede training of U.S. scientists.
The FIC fosters research collaborations between U.S. and overseas institutions to develop treatments that reduce disability and save lives. Although the center has the smallest budget among the NIH's 27 institutes and centers ($70.4 million in fiscal year 2016), FIC grantees have been among the most productive in publishing peer-reviewed articles (see graph). In 2015, researchers supported by the center published more than 20 articles per $1 million of annual budget. Applications for FIC grants are highly competitive. In fiscal year 2016, applicants for a K01 careerdevelopment award from the center had a 22.7% success rate, as compared with 32.1% for such awards across all NIH institutes.
The FIC has funded wide-ranging studies whose findings are relevant to major health issues in the United States and elsewhere. FIC-supported researchers are working to improve stroke prevention, treat multidrug-resistant tuberculosis, and evaluate HIV vaccine candidates. FIC-funded efforts are tackling the problem of fake medications that kill millions of patients worldwide and that many Americans purchase unwittingly; identifying new cancer drugs in the waters off the Panama coast; and finding ways to address the number-one killer of young American travelers, road traffic accidents.
About one third of FIC grants focus on scientific discovery, and two thirds support research training. The center's training programs have been a model of sustained, mission-driven efforts to equip U.S. scientists and their colleagues in low-and middleincome countries (LMICs) to collaboratively tackle the world's health challenges. trainees supported by this program at 61 sites in 27 countries through 2012 showed that they had sustained engagement in research (67% success rate with subsequent grant applications) and that grantees considered the FIC funding to have been pivotal in establishing their careers and allowing them to develop the skills to mentor other research trainees. 2 Topics investigated by FIC trainees had substantial relevance to U.S. health conditions, including both infectious diseases (especially HIV-AIDS) and noncommunicable diseases; grants also cover research in basic science, health systems, and health behavior. 2 The majority of fellows are of U.S. origin, so the program represents an unusual and successful investment in U.S. research capacity as well as diplomacy, yielding substantial research productivity, providing future research leaders with training experiences not available in the United States, and fostering supportive international relationships.
The The FIC's capacity-building investments are also facilitating innovative research in noncommunicable diseases. A region of Colombia has one of the highest rates of early-onset Alzheimer's disease in the world. The FIC and the National Institute on Aging supported the development of a U.S.-Colombian collaboration investigating this cohort, which laid the foundation for the first clinical trial of a U.S.-manufactured antiamyloid therapy to prevent Alzheimer's disease. The FIC has been instrumental in extending the frontiers of health research around the globe and ensuring that advances in science are implemented to reduce the burden of disease, promote health, and extend longevity for all people. By facilitating rare training experiences for U.S. scientists in LMICs, the center has created a cadre of productive researchers with the capacity to find solutions with regard to global diseases such as Zika and Ebola that will continue to threaten human health everywhere. FIC funding of training experiences for LMIC researchers has undergirded the NIH's capacity to conduct multinational studies, yielding insights that have transformed the care of patients in the United States and many other countries. For these reasons, we believe the U.S. Congress, the President, and the NIH should ensure that the FIC's funding is sustained. Preservation of the FIC and its globally oriented mission represents a critical investment in the health of the American people as well as the global community.
